Staff

Paride Pelucchi

Ricercatore
E-Mail

paride.pelucchi@cnr.it

PHONE

none

LOCATION

Segrate

ROOM (floor/number)

6/20

I graduated cum laude in Biotechnology in July 2004, and I obtained a PhD in Molecular Medicine (curriculum: Genomics, Proteomics and Related Technologies) in January 2008, both at the University of Milan. Since 2012 I am a researcher of the ITB-CNR. My research is focused on the characterization of genetic and epigenetic networks underlying stem cell properties in physiological context and pathologies, especially for oncological ones (Cancer Stem Cells). The study of stem cell mechanisms has also been applied to somatic reprogramming to Induced Pluripotent Stem Cells (iPSCs), which are used also for disease modelling. In this context were developed complex cell systems (e.g. organoids), which were studied using effective and high-resolution molecular approaches such as single-cell transcriptomics, that I implemented and applied. With extensive skills in both molecular and cellular biology, I developed lentivirus-based systems for the expression modulation or sequence engineering of specific genes and microRNAs and applied them on in vitro disease models. Furthermore, I added epigenetic approaches (ChIP-Seq, ATAC-seq, etc.) to traditional transcriptomics in the characterization of the molecular mechanisms underlying specific pathologies.

Post-transcriptional regulation of protein translation by synthetic lncRNA SINEUPs to restore protein levels in haploinsufficient-loss of function genetic diseases

Development of high-throughput CRISPR screening platforms, integrating machine learning-guided library design with large-scale genetic perturbation experiments in different biological contexts

Characterization of the functional landscape of single nucleotide variants (SNV) in disease models by using large-scale CRISPR screens and quantifying variant effects via phenotypic and transcriptional readouts

Determination of how Single Nucleotide Variants (SNVs) in RNA-modification effectors influence cancer cell proliferation and drug resistance